| Title |
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
|
|---|---|
| Published in |
Advances in Therapy, September 2016
|
| DOI | 10.1007/s12325-016-0413-7 |
| Pubmed ID | |
| Authors |
Jesus F. San-Miguel, Hermann Einsele, Philippe Moreau |
| Abstract |
Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the treatment of relapsed or relapsed and refractory multiple myeloma (MM) in patients who have received ≥2 prior regimens including bortezomib and an immunomodulatory drug. In January 2016, the National Institute for Health and Care Excellence recommended panobinostat for use in the same combination and patient population. The authorization and recommendation were based on results from the pivotal phase 3 PANORAMA 1 (NCT01023308) clinical trial, which demonstrated an improvement in median progression-free survival of 7.8 months for the three-drug combination compared with placebo plus bortezomib and dexamethasone in this patient population. This review will discuss the current treatment landscape for relapsed/refractory MM, the mechanism of action of panobinostat, clinical data supporting the European authorization, concerns about safety and strategies for mitigating toxicity, and how panobinostat fits into the current MM landscape in Europe. Editorial support, funded by Novartis Pharmaceuticals. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 19% |
| Student > Bachelor | 5 | 16% |
| Student > Ph. D. Student | 5 | 16% |
| Student > Postgraduate | 4 | 13% |
| Other | 4 | 13% |
| Other | 6 | 19% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 16% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Agricultural and Biological Sciences | 3 | 9% |
| Economics, Econometrics and Finance | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 3 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2016.
All research outputs
#18,472,072
of 22,889,074 outputs
Outputs from Advances in Therapy
#1,637
of 2,354 outputs
Outputs of similar age
#245,209
of 322,819 outputs
Outputs of similar age from Advances in Therapy
#24
of 34 outputs
Altmetric has tracked 22,889,074 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,354 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,819 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.